Recently, Chair of the National Institute for Clinical Excellence (NICE), Sir Michael Rawlins, has accused a number of trusts for not providing vital medications and treatment to the patients. Sir Michael Rawlins was reported as saying, “Numerous trusts are acting unlawfully. Although they know they are required to make Nice-approved products available, they introduce delaying tactics”.

He has encouraged the patients and charities to sue the trusts which are saying no to vital treatments. Sir Michael’s has lamented series of allegation over the working of the trusts in a journal, Health Service.

While writing in the journal, Sir Michael said that trusts are delaying the administration of drugs to the patients with the pursuit of saving some money. This practice has affected the health of many patients.

A treatment called dexamethasone intravitreal implants has been approved by NICE for the clinical use on the patients of retinal vein occlusion. However, it has been found that many trusts are not providing this treatment to the patients. Sir Michael has asked the patients to sue such trusts. A judicial review over such trusts has been asked by Sir Michael. Patients have the right to get treated and trusts are putting the health of the patients at stake by not providing them treatment.